Bulk Suggestion Bulk ID: braviboron/08.21.25-07:37AM
Rejected at: Oct, 06, 2025 8:02 p.m.
Author: braviboron
Related Deck: 1675118865074
Rejected
Rationale for new note

This completes NMS

Rejection reason

Duplicate

Text
Text
What drug classes can&nbsp;<u>cause</u> of <b>neuroleptic malignant syndrome</b>&nbsp;after ingestion or withdrawal?<br><br>{{c1::Recent administration of a dopamine antagonist or withdrawal from a dopaminergic drug}}
Extra
Empty field
Extra
Extra (Synced)
Empty field
Extra (Synced)
Personal Notes
Empty field
Personal Notes
Missed Questions
Empty field
Missed Questions
eTG Complete
Empty field
eTG Complete
Talley & O'Connor
Empty field
Talley & O'Connor
Additional Resources
Empty field
Additional Resources
Additional Resources (Synced)
Empty field
Additional Resources (Synced)
Source
Source
eTG - Neuroleptic malignant syndrome <a href="https://app-tg-org-au.ap1.proxy.openathens.net/viewTopic?etgAccess=true&amp;guidelinePage=Toxicology%20and%20Toxinology&amp;topicfile=toxidrome-neuroleptic-malignant&amp;guidelinename=Toxicology%20and%20Toxinology&amp;sectionId=toc_d1e168#toc_d1e168">https://app-tg-org-au.ap1.proxy.openathens.net/viewTopic?etgAccess=true&amp;guidelinePage=Toxicology and Toxinology&amp;topicfile=toxidrome-neuroleptic-malignant&amp;guidelinename=Toxicology and Toxinology&amp;sectionId=toc_d1e168#toc_d1e168</a> Published/Amended August 2020, Accessed 21 August 2025
One by one
Empty field
One by one
Tags
#Malleus_CM::#eTG_Complete::Toxicology_and_Toxinology::Toxidromes::Neuroleptic_malignant_syndrome #Malleus_CM::#Resources_by_Rotation::Anaesthetics #Malleus_CM::#Resources_by_Rotation::Emergency #Malleus_CM::#Subjects::Critical_Care::05_Exposure::01_Drug-related_Disorders::Neuroleptic_Malignant_Syndrome::03_Risk_Factors